Basilea reports strong, higher than expected preliminary

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2022
128
Basilea reports strong, higher than expected preliminary revenue of CHF 133 million for financial year 2018

Basel, Switzerland, January 07, 2019 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announced today the unaudited preliminary revenue for the financial year 2018. Total revenue is expected to increase by 31% over 2017 to approx. CHF 133 million (FYR 2017: CHF 101.5 million), with contributions of approx. CHF 82 million (FYR 2017: CHF 52.5 million, + 56%) from Basilea's two marketed products, the antifungal Cresemba ® (isavuconazole) and the antibiotic Zevtera ® (ceftobiprole). Basilea had guided for total revenue of CHF 120-130 million and contributions from Cresemba and Zevtera of CHF 75-85 million for the financial year 2018.

David Veitch, Chief Executive Officer of Basilea commented: "We are very pleased with our preliminary revenue of CHF 133 million, which exceeds our guidance. The increase of 56% in the revenue contributions from our two marketed products, Cresemba and Zevtera, confirms in particular the continued strong sales ramp-up of Cresemba, both in established markets and the more recently launched markets. Against the background of the continued high unmet medical need of patients suffering from invasive mold infections and the significant number of upcoming country launches, we are very positive for the future sales prospects of the brand."

He added: "In addition to exceeding our top line revenue target, we have achieved several important strategic milestones in 2018. Amongst others, we have initiated both phase 3 studies for ceftobiprole required to support a potential U.S. registration and have successfully expanded our oncology R&D portfolio through the in-licensing of the panFGFR kinase inhibitor derazantinib, which is currently recruiting patients in the registrational phase 2 study in intrahepatic cholangiocarcinoma. Our solid cash position of approx. CHF 223 million as of December 31, 2018 (preliminary, unaudited) provides us with the financial flexibility to execute on our strategy towards achieving the upcoming key value inflections in our R&D pipeline."

The audited full financial statements as well as the annual report 2018 will be published on February 19, 2019. The final audited revenue for 2018 and the cash position as of year-end 2018 may differ from the reported preliminary numbers.

About Basilea Basilea Pharmaceutica Ltd. is a commercial stage biopharmaceutical company, focusing on the development of products that address the medical challenges in the therapeutic areas of oncology and anti-infectives. With two commercialized drugs, the company is committed to discovering, developing and commercializing innovative pharmaceutical products to meet the medical needs of patients with serious and life-threatening conditions. Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland and listed on the SIX Swiss Exchange (SIX: BSLN). Additional information can be found at Basilea's website www.basilea.com .

Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

For further information, please contact:

Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations +41 61 606 1102 media_relations@basilea.com investor_relations@basilea.com

This press release can be downloaded from www.basilea.com .

Attachment

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Union Pacific Faces $98.8 Million Arbitration Tab

Updated Category News Views 143

A Missed Schedule Promise Got Very Expensive Railroad labor disputes can look like paperwork until the bill lands with a thud. Union Pacific is facing an estimated $98.8 million arbitration payout after a Special Board of Adjustments found that the carrier failed to implement a negotiated scheduling benefit for locomotive engineers. That is not loose change, and it is the...

Continue Reading
Travel Awards Spotlight Luxury Hospitality's Reach

Updated Category News Views 90

Hong Kong’s awards roll call reads less like a scorecard than a map of where premium travel wants its money and attention to go next. The 2026 World’s Travel & Hotel Awards, released November 20, cast a very wide net: heritage palaces, city hotels, beach retreats, airlines, cruise operators, tourism boards, restaurants, serviced apartments and a fair number of...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Lara Kirchner's Surgical Leadership Earns Recognition

Updated Category News Views 83

Surgical care gets judged in the quiet moments nobody puts on a plaque: a sterile instrument ready when it must be, a handoff done cleanly, a team that does not let a rushed schedule turn into a bad outcome. That is why Lara L. Kirchner's recognition as a Pinnacle Professional of the Year deserves a more serious look than the usual congratulatory confetti. Kirchner is...

Continue Reading
ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Nansha's Trade Pitch Has Numbers, but Questions Remain

Updated Category News Views 112

A Chilean cherry spending 22 days at sea can tell an investor plenty about where Guangzhou's Nansha District wants to sit in Asia-Pacific commerce. Not glamorous, no. But trade infrastructure rarely is until volumes pile up, routes deepen, and somebody else finds they cannot easily replicate the network. Nansha is using the expected 33rd APEC Economic Leaders' Meeting in...

Continue Reading
CVRx Lawsuit Puts Barostim Sales Claims Under Hard Scrutiny

Updated Category News Views 121

August 7 turned a compliance disclosure into a wrecking ball for CVRx shareholders. After the company revealed a Department of Justice civil investigative demand and cut its outlook, the stock dropped $3.55, or 60%, to close at $2.39. That is not a routine bad quarter getting punished. It is the market abruptly questioning whether the sales engine, the revenue it...

Continue Reading
Rock Gate Buys Aviation Niche Player Blast Deflectors

Updated Category News Views 167

Jet exhaust is not glamorous, but somebody has to keep it from battering everything nearby. Rock Gate Partners’ acquisition of Blast Deflectors, Inc. puts money behind one of those stubbornly unsexy industrial niches where engineering credibility matters far more than a flashy sales pitch. The transaction closed October 16, 2026, and Northborne Partners announced...

Continue Reading
Swim Readiness Depends on Skills, Not Birthdays Alone

Updated Category News Views 55

A child popping up calmly after a brief dunk tells you more than a birthday ever will. That is the sensible center of Woody Alpern's guidance for families weighing whether a child belongs in the next swim level. The Atlanta swim school expert's point is refreshingly free of the usual parental race: advancement is earned through repeatable skills, comfort, and judgment in...

Continue Reading
GEYOTO’s RE+ Debut Shows Demand, Not Yet Scale Proof

Updated Category News Views 39

Desert-colored booths do not pay invoices, but a nearly sold-out stash of spare units is a lot more useful than the usual trade-show applause. GEYOTO’s first RE+ appearance, held November 17–19 at the Las Vegas Convention Center, produced the kind of early evidence a young energy-products brand needs: people stopped, handled the equipment, asked questions, made...

Continue Reading

Top 5 Most Recently Viewed Articles

AI Data Risks and the Urgent Need for Enhanced Security Measures

Updated Category News Views 233

AI Data Security Threats Revealed by Varonis In a recent study conducted by Varonis, a prominent data security firm, alarming findings have surfaced regarding the vulnerabilities in organizations’ data systems. The report indicates that an overwhelming 99% of businesses have sensitive data that is exposed to artificial intelligence (AI) tools. This raises significant...

Continue Reading
Volt Lithium's Groundbreaking Daily Output Achieved with New Tech

Updated Category News Views 170

Volt Lithium Achieves Remarkable Milestone Volt Lithium Corp. is excited to announce that it has completed a 24-hour continuous run of its Generation 5 Field Unit, achieving an impressive throughput of 11,573 barrels per day. This significant milestone not only exceeds the initial target of 10,000 barrels per day but also demonstrates the company’s rapid advancements in...

Continue Reading
Investors Urged to Act Before PepGen Legal Deadline Approaches

Updated Category News Views 169

Urgent Reminder for PepGen Investors As the deadline approaches, it is vital for affected investors to take immediate action regarding their stakes in PepGen Inc. The renowned law firm, Bragar Eagel & Squire, P.C., is advocating for those who have incurred losses related to their investments in PepGen (PEPG). If you have purchased or otherwise acquired securities in...

Continue Reading
Gaumont's Voting Rights and Share Capital Information Revealed

Updated Category News Views 166

Gaumont’s Recent Disclosure on Voting Rights and Share Capital Gaumont, a well-known name in the film industry, recently shared important details about its voting rights and share capital. This information is crucial for current and prospective investors, providing transparency and clarity regarding the company’s governance structure. Key Details as per Article L....

Continue Reading
EAM-Mosca to Showcase Innovative Packaging Solutions at Expo

Updated Category News Views 170

EAM-Mosca to Showcase Innovative Packaging Solutions at SuperCorr Expo EAM-Mosca is excited to announce its participation in the upcoming SuperCorr Expo, where it will present its latest state-of-the-art strapping and wrapping solutions at Booth #2031. Attendees will have the opportunity to see firsthand how these solutions can improve efficiency and provide enhanced...

Continue Reading